Sign inJoin waitlistJoin the waitlist

Shail Maingi

Network Liaison, Cancer Care Access Program · Mass General Brigham

Credentials: · · · · · · ·

History

Dana-Farber Cancer Institute
2022–Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2006–2009
Montefiore Einstein
2003–2006
Temple University School of Medicine
1999–2003

Research

American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations
Journal of Clinical Oncology · 2017 · 225 citations
Experiences of Lesbian, Gay, Bisexual, and Transgender Patients and Families in Hospice and Palliative Care: Perspectives of the Palliative Care Team
Journal of Palliative Medicine · 2020 · Last of 6 authors · 67 citations
Sexual Orientation and Gender Identity Data Collection in Oncology Practice: Findings of an ASCO Survey
JCO Oncology Practice · 2022 · 64 citations

Sean O'Mahony
11 papers
Asa Radix
3 papers
Carl Streed
2 papers
Don Dizon
2 papers
Alec Gibson
1 paper
Alex Keuroghlian
1 paper
Alok Khorana
1 paper
AB
Arthur Bagabag
1 paper
Bruce Scott
1 paper
Carly Guss
1 paper
CK
Charles Kamen
1 paper
Charles Thomas
1 paper

Clinical trials

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Site PI · Recruiting
Dana-Farber Cancer Institute
2025–2030
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2039
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027